Skip to content

SPECT/CT guided precise diagnosis and injection of dystonic muscles in cervical dystonia

SPECT/CT guided precise diagnosis and injection of dystonic muscles in cervical dystonia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042352
Enrollment
Unknown
Registered
2021-01-19
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical distonia (CD)

Interventions

experimental group:Based on SPECT examination, botulinum toxin is concentrated in the radiation-rich area of the muscles responsible for spasm
control group:Based on SPECT examination, botulinum toxin is evenly distributed in the muscles responsible for spasm.

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-75 years, no gender limit; (2) Subjects have a clear understanding of the purpose of the study, are willing and able to complete the study, and sign informed consent; (3) Meet the diagnostic criteria for primary CD; (4) The symptoms of CD lasted for at least 1 month; (5) No history of surgical treatment for CD, and oral antispasmodic drugs were not effective; (6) No history of BTX-A injection or at least 3 months from the last injection.

Exclusion criteria

Exclusion criteria: (1) Congenital muscular torticollis or abnormal head and neck posture due to tumor, trauma, drugs, and other factors; (2) Patients with primary CD only manifested as tremor; (3) Unwillingness to receive BTX-A injection or allergy to BTX-A and its related components; (4) Patients who are currently taking medications interfering with neuromuscular conduction; (5) Pregnant and lactating women; (6) Infections or skin lesions at the injection sites; (7) Patients with unstable severe cardiovascular, renal, and respiratory system diseases; (8) Patients with severe cognitive impairment or mental illness that affected the clinical evaluation.

Design outcomes

Primary

MeasureTime frame
TWSTRS score reduction rate;

Secondary

MeasureTime frame
Tsui score reduction rate;Number of injection sites;Time spent in treatment;VAS pain score;

Countries

China

Contacts

Public ContactJin Lingjing

Shanghai Tongji Hospital

lingjingjin@163.com+86 15021312377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026